Roth Still Positive on Cytori (CYTX) as ACT-OA Phase 2 Commences

Roth Capital affirms Cytori Therapeutics (Nasdaq: CYTX) at Buy with a price target of $6 following news that the first patient has been treated in its Phase II ACT-OA study of Cytori Cell Therapy in osteoarthritis (OA) patients.

Analyst Joseph Pantginis said, We're encouraged by the progress in the OA program, which aims to develop a novel therapeutic opportunity to OA patients who have limited non-surgical options. Such a new therapy could help not only the patients' well being and expand the arsenal for treating physicians, but also help unburden the healthcare system from costs associated with OA such as ambulatory care and hospitalizations, including total knee replacements. We believe there is significant potential opportunity for Cytori's approach, should the product reach the market, based on these factors and on the high prevalence of OA in the U.S. We believe that treating orthopedic doctors are in need of new nonsurgical procedures to treat their patients as current available options are not satisfactory. Data from this study are expected in 2016.

For an analyst ratings summary and ratings history on Cytori Therapeutics, Inc. click here. For more ratings news on Cytori Therapeutics, Inc. click here.

Cytori Therapeutics, Inc. closed at $0.47 yesterday.

You May Also Be Interested In

• Jefferies Downgrades Calix (CALX) to Hold
• Meta Platforms Inc. (META) PT Lowered to $570 at RBC Capital
• Meta Platforms Inc. (META) PT Lowered to $550 at Citi